Drug class profile · refreshed daily from federal data

Aminosalicylate

3 molecules in this class, $511.7M combined CY2024 Part D spend across 2.0M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Aminosalicylate class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $511.7Mcombined across class
Total Rx claims: 2.0M601K unique beneficiaries
Generic mfrs (active): 32across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Mesalamine

Brand: APRISO · 972K Part D claims (CY24) · 284K beneficiaries · First FDA approval: 1993-05-10

23 generic mfrs 1 plans require PA

Low NADAC$0.106

→

Avg plan cost$6.75

Part D spend $454.7M 64× spread, current vs floor

Class share

89%

of class CY24 spend

View profile →

Sulfasalazine

Brand: Azulfidine · 877K Part D claims (CY24) · 273K beneficiaries · First FDA approval: 1950-06-20

4 generic mfrs 0 plans require PA

Low NADAC$0.197

→

Avg plan cost$0.210

Part D spend $29.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Balsalazide Disodium

160K Part D claims (CY24) · 44K beneficiaries · First FDA approval: 2007-12-28

5 generic mfrs 0 plans require PA

Low NADAC$0.360

→

Avg plan cost$0.360

Part D spend $27.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.